Sector News

Merck & Co rumoured to be in talks to buy Cubist

December 8, 2014
Life sciences
Merck & Co is rumoured to be in talks to acquire Cubist Pharmaceuticals with a price of $7-$8 billion being mentioned for the antibiotics specialist.
 
Reports of a deal surfaced in the New York Times, prompting a 26% leap in after-hours trading for Cubist stock to $93.50. The companies are not commenting on the rumours but the newspaper cited unnamed sources as saying Merck could pay $100 a share, valuing Cubist at about $7.5 billion; a deal could be announced as early as this week, the NYT claims.
 
Cubist posted revenues of $864.8 million in the first nine months of 2014, most of which came from the antibacterial Cubicin (daptomycin). In June, the US Food and Drug Administration approved Cubist’s Sivextro (tedizolid) for serious skin infections.
 
A tie-up with Cubist, which is regularly mentioned as a takeover target, would make sense for Merck which recently saw its antibiotic relebactam fast-tracked by the FDA.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 30, 2020

Johnson & Johnson signs on Michigan’s Grand River to help with COVID-19 vaccine finishing work

Life sciences

With all eyes on the hunt for a COVID-19 vaccine, drugmakers like New Jersey’s Johnson & Johnson are scouring the market for manufacturing partners to help meet what would be […]

September 30, 2020

Takeda taps Elektrofi’s microparticle delivery platform for potential subq plasma offerings

Life sciences

Takeda has joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could enable simpler dosing with plasma-derived therapies. Takeda will assess Elektrofi’s drug delivery platform using […]

September 29, 2020

Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion

Life sciences

Novo Nordisk wants the heart disease community to join the diabetes conversation. As Type 2 diabetes drugs nab approvals for reduced cardiovascular risks—including Novo’s own Ozempic and Victoza—the need to […]